• New York State health regulators cleared Quest Diagnostics’ Haystack MRD ctDNA test for minimal residual disease detection in solid tumors.
• The decision opens patient testing in New York, making the assay available across all 50 U.S. states.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quest Diagnostics Incorporated published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606240852PR_NEWS_USPR_____NY90479) on June 24, 2026, and is solely responsible for the information contained therein.